key: cord-0800295-rkrmcmzu authors: Bouazza, Belaid; Ramdani, Idir; Chahed, Rachid title: Chloroquine and COVID-19: role as a bitter taste receptor agonist? date: 2021-01-24 journal: New Microbes New Infect DOI: 10.1016/j.nmni.2021.100843 sha: 047e895665e5848b223a0f37cbdf8a78cb2dfe59 doc_id: 800295 cord_uid: rkrmcmzu nan The world is facing a global health crisis called Coronavirus disease 2019 (COVID-19) caused by the novel coronavirus: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 infection was first identified in China in December 2019 [1] but quickly spread all over the world affecting over 73 million persons and causing more than 1.6 million deaths [2]. COVID-19 patients may experience different symptoms ranging from mild to severe illness including fever, cough, congestion, fatigue, loss of taste or smell, chest pain and difficulty breathing [3] . The disease severity depends on age, sex and comorbidities including chronic respiratory diseases [4] . Although the literature remains divided about the impact of asthma [5], chronic obstructive pulmonary disease (COPD) is one of the most reported comorbidities in COVID-19 patients, and is related to disease severity, intensive care unit admission and mortality [6] [7] [8] . Chronic respiratory diseases are characterized by chronic airway inflammation and bronchial hyperresponsiveness that may lead to exacerbation following viral infections (VIs). VIs are known to affect dramatically both asthma and COPD [9] [10] [11] , resulting in airway smooth muscle (ASM) contraction and airway obstruction. Indeed, VIs including the common coronavirus, are responsible for up to 80% of asthma exacerbations [12] . Similarly, like other coronaviruses, SARS-CoV-2 may exacerbate asthma, although the underling molecular mechanisms through which this may occur are still unknown [13] . Hence, SARS-CoV-2, infects bronchial epithelium causing tissue damage and mucus accumulation [14] thus decreasing lung function [15] . In J o u r n a l P r e -p r o o f addition, asthma exacerbation has been reported to be associated with COVID-19 pneumonia [16, 17] and mortality [18] . Even though vaccine campaigns started in the UK and USA for the most vulnerable individuals [19, 20] , a vaccine will not be available soon to all countries around the world. Specific treatments are lacking, but many drugs were repurposed to treat COVID-19, including antivirals (Lopinavir, Ritonavir, Remdesivir), antibiotics (Azithromycin, Teicoplanin), Chloroquine/Hydroxychloroquine, glucocorticoids and bronchodilators [21] . In fact, the use of both reliever and controller treatments were increased in asthmatic children with COVID-19 compared to those without COVID-19 [22] . Moreover, physicians recommended and used bronchodilators to relax airways of COVID-19 patients with chronic respiratory diseases [23] to help them improve their health condition and reduce ventilator needs [24] . Chloroquine (CQ) is used for the treatment of different diseases, such as malaria, rheumatoid arthritis and erythematous lupus [25] and it successfully inhibited the SARS-CoV-2 replication in vitro [26] . Although scientists remain divided on its efficacy against COVID-19, no harmful effect was demonstrated [27] . However, some studies concluded that CQ was effective in viral clearance and in improving COVID-19 patients' prognosis [28] [29] [30] . The beneficial effect of CQ is related to its role in immunomodulation and inhibition of viral replication [31] . On the other hand, CQ is a bitter taste receptor (TAS2R) agonist activating four receptor subtypes [32] , expressed in extra-oral tissues including ASM and epithelium [33] . Moreover, their activation leads to relaxation of pre-contracted human ASM similar to that induced by beta 2 agonists [34] , and prevention of airways hyperresponsiveness and mucus accumulation in a murine model of asthma [35] . Interestingly, the relaxation induced by TAS2R agonists is unaffected by beta agonist tachyphylaxis [36] . Of importance, many bitter compounds were suggested to be used to treat COVID-19 [37] , and CQ efficacy was shown to decrease in J o u r n a l P r e -p r o o f obese COVID-19 patients, where TAS2Rs are downregulated [38] . Moreover, no association between chronic respiratory diseases and severity of SARS-CoV-2 infection was observed when COVID-19 patients were treated with CQ [29, 39, 40] . These observations suggest that the TAS2R agonist; CQ, may have a role, in airway relaxation, bronchodilation and in preventing disease severity of COVID-19 patients. WHO | Pneumonia of unknown cause -China Johns Hopkins Coronavirus Resource Center COVID-19: Epidemiology, Pathophysiology, Transmission, Symptoms Outcome Disparities Among Men and Women With COVID-19: An Analysis of the New York City Population Cohort Asthma prolongs intubation in COVID-19 Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19 Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19) SARS-CoV-2 infection in the COPD population is associated with increased healthcare utilization: An analysis of Cleveland clinic's COVID-19 registry Viruses and asthma: the role of common respiratory viruses in asthma and its potential meaning for SARS-CoV-2 Role of viral respiratory infections in asthma and asthma exacerbations Emergency department visits and hospitalisations for asthma, COPD and respiratory tract infections: what is the role of respiratory viruses, and return to school in September Treatment of COVID-19-exacerbated asthma: should systemic corticosteroids be used? Chest CT features of coronavirus disease 2019 (COVID-19) pneumonia: key points for radiologists Pulmonary function of patients with 2019 novel coronavirus induced-pneumonia: a retrospective cohort study Asthma exacerbation associated with COVID-19 pneumonia Clinical course of asthma in 4 cases of coronavirus disease 2019 infection Impact of comorbid asthma on severity of coronavirus disease (COVID-19) Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine CDC. Vaccine Testing and Approval Process | CDC COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment Impact of the COVID-19 pandemic in children with allergic asthma The top 2 meds prescribed for COVID-19 patients Clinical course of asthma in 4 cases of coronavirus disease 2019 infection Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 Lowdose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 Hydroxychloroquine and covid-19 The Molecular Receptive Ranges of Human TAS2R Bitter Taste Receptors Analysis of the expression of human bitter taste receptors in extraoral tissues Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction Bitter Taste Receptor Agonists Mitigate Features of Allergic Asthma in Mice TAS2R activation promotes airway smooth muscle relaxation despite β(2)-adrenergic receptor tachyphylaxis Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases The influence of bittertaste receptor (TAS2R) expression in pharmacological response to Chloroquine in obese patients with COVID-19 Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State Lowdose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants